The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Key papers in cardio-oncology from 2023 of relevance to hematologists
In this video, Alex Lyon, MA, BM BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, outlines some of the key papers in the field of cardio-oncology from 2023 that are relevant to hematologists. These include a paper on the International Late Effects of Childhood Cancer Guideline Harmonization, a meta-analysis assessing dexrazoxane for the prevention of anthracycline cardiotoxicity, and the STOP-CA trial (NCT02943590) investigating the use of atorvastatin for preventing this same complication. Additionally, a paper examining radiation doses highlighted that reducing mean heart exposure over decades reduced the risk of cardiac and ischemic events. Dr Lyon also comments on a publication examining reported cardiac events in patients receiving CAR T-cell therapy for hematological indications. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
